Ionis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Ionis Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 35.3% bzw. 20.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 38.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -557.9% betragen.

Wichtige Informationen

35.3%

Wachstumsrate der Gewinne

38.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	20.1%
Zukünftige Eigenkapitalrendite	-557.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Recent updates

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:IONS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,069	-314	-366	-324	16
12/31/2025	767	-520	-554	-450	21
12/31/2024	598	-573	-519	-428	22
3/31/2024	777	-385	-345	-323	N/A
12/31/2023	788	-366	-336	-308	N/A
9/30/2023	615	-409	-574	-541	N/A
6/30/2023	631	-309	-493	-456	N/A
3/31/2023	576	-329	-405	-377	N/A
12/31/2022	587	-270	-294	-274	N/A
9/30/2022	875	7	110	130	N/A
6/30/2022	849	-28	82	98	N/A
3/31/2022	841	-4	35	54	N/A
12/31/2021	810	-29	13	31	N/A
9/30/2021	661	-608	-96	-75	N/A
6/30/2021	688	-550	-59	-30	N/A
3/31/2021	708	-495	-45	-11	N/A
12/31/2020	729	-444	-5	36	N/A
9/30/2020	933	94	173	216	N/A
6/30/2020	940	145	165	213	N/A
3/31/2020	959	169	188	230	N/A
12/31/2019	1,123	281	309	346	N/A
9/30/2019	821	433	154	183	N/A
6/30/2019	799	402	154	170	N/A
3/31/2019	752	366	679	697	N/A
12/31/2018	600	277	585	603	N/A
9/30/2018	575	-41	485	508	N/A
6/30/2018	548	-38	525	563	N/A
3/31/2018	543	9	28	65	N/A
12/31/2017	514	19	N/A	174	N/A
9/30/2017	507	42	N/A	127	N/A
6/30/2017	499	52	N/A	122	N/A
3/31/2017	426	-15	N/A	86	N/A
12/31/2016	373	-60	N/A	-112	N/A
9/30/2016	238	-184	N/A	-123	N/A
6/30/2016	176	-227	N/A	-111	N/A
3/31/2016	258	-134	N/A	-12	N/A
12/31/2015	284	-88	N/A	21	N/A
9/30/2015	317	14	N/A	129	N/A
6/30/2015	312	23	N/A	95	N/A
3/31/2015	249	-24	N/A	-4	N/A
12/31/2014	214	-39	N/A	6	N/A
9/30/2014	172	-94	N/A	-79	N/A
6/30/2014	151	-92	N/A	-15	N/A
3/31/2014	132	-90	N/A	42	N/A
12/31/2013	147	-61	N/A	63	N/A
9/30/2013	125	-39	N/A	114	N/A
6/30/2013	113	-52	N/A	23	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IONS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IONS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IONS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IONSDie Einnahmen des Unternehmens (20.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: IONSDie Einnahmen des Unternehmens (20.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IONS wird voraussichtlich in 3 Jahren unrentabel sein.

Ionis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Price target decreased by 7.2% to US$47.48

Consensus forecasts updated

Recent updates

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals Looks Good For The Long Term

Ionis plans for new manufacturing site in California to support pipeline

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Ionis: 2 Drug Advancements With Potential Firsts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ionis Pharmaceuticals Q2 2022 Earnings Preview